Don Bergstrom, M.D., Ph.D.

As President, R&D, Don Bergstrom oversees Relay Therapeutics’ research and development efforts and shapes the Company’s portfolio of transformative medicines based on an understanding of protein motion. Prior to Relay Therapeutics, Don was chief medical officer at Mersana Therapeutics, where he oversaw the non-clinical and early clinical development of the first two products from Mersana’s proprietary antibody-drug conjugate platform. Prior to Mersana, he held leadership roles in translational medicine and early clinical development at Sanofi and Merck. Over his career in industry, Don has been a scientific leader on more than 15 successful IND applications and the development of five marketed drugs. Don sits on the Board of Directors of Fusion Pharmaceuticals and Cellectis.

Don holds an M.D. from the University of Washington, Seattle and a Ph.D. from the Fred Hutchinson Cancer Research Center, where he also completed post-doctoral training. He was a resident in clinical pathology at the University of Washington.